Kancera AB (publ) (KAN.ST)
SEK 1.13
(9.51%)
SEK 1.13
(9.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 63.07 Million SEK | 19.72% |
| 2022 | 52.68 Million SEK | 12.2% |
| 2021 | 46.96 Million SEK | -4.61% |
| 2020 | 49.23 Million SEK | 26.13% |
| 2019 | 39.03 Million SEK | -16.5% |
| 2018 | 46.74 Million SEK | -17.0% |
| 2017 | 56.31 Million SEK | 150.0% |
| 2016 | 22.52 Million SEK | 13.24% |
| 2015 | 19.89 Million SEK | 22.36% |
| 2014 | 16.25 Million SEK | 39.12% |
| 2013 | 11.68 Million SEK | -65.89% |
| 2012 | 34.26 Million SEK | 27.8% |
| 2011 | 26.81 Million SEK | 274.05% |
| 2010 | 7.16 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.35 Million SEK | -15.24% |
| 2024 Q1 | 13.39 Million SEK | -31.06% |
| 2023 Q3 | 10.54 Million SEK | -43.84% |
| 2023 Q4 | 19.42 Million SEK | 84.23% |
| 2023 FY | 63.07 Million SEK | 19.72% |
| 2023 Q2 | 18.77 Million SEK | 8.41% |
| 2023 Q1 | 17.32 Million SEK | 23.74% |
| 2022 Q4 | 14 Million SEK | 27.91% |
| 2022 Q3 | 10.94 Million SEK | -28.77% |
| 2022 Q1 | 12.15 Million SEK | -12.39% |
| 2022 Q2 | 15.36 Million SEK | 26.46% |
| 2022 FY | 52.68 Million SEK | 12.2% |
| 2021 Q4 | 13.86 Million SEK | 22.63% |
| 2021 FY | 46.96 Million SEK | -4.61% |
| 2021 Q1 | 9 Million SEK | -42.03% |
| 2021 Q2 | 18.24 Million SEK | 102.62% |
| 2021 Q3 | 11.3 Million SEK | -38.0% |
| 2020 Q2 | 17.45 Million SEK | 56.67% |
| 2020 FY | 49.23 Million SEK | 26.13% |
| 2020 Q3 | 9.37 Million SEK | -46.33% |
| 2020 Q4 | 15.52 Million SEK | 65.73% |
| 2020 Q1 | 11.14 Million SEK | 47.45% |
| 2019 Q1 | 7.9 Million SEK | -37.74% |
| 2019 FY | 39.03 Million SEK | -16.5% |
| 2019 Q4 | 7.55 Million SEK | -1.84% |
| 2019 Q3 | 7.7 Million SEK | -39.09% |
| 2019 Q2 | 12.64 Million SEK | 60.01% |
| 2018 Q4 | 12.69 Million SEK | 19.22% |
| 2018 FY | 46.74 Million SEK | -17.0% |
| 2018 Q3 | 10.64 Million SEK | 4.86% |
| 2018 Q2 | 10.15 Million SEK | -18.7% |
| 2018 Q1 | 12.48 Million SEK | 3.76% |
| 2017 FY | 56.31 Million SEK | 150.0% |
| 2017 Q2 | 18.02 Million SEK | 86.01% |
| 2017 Q1 | 9.69 Million SEK | 46.59% |
| 2017 Q3 | 16.56 Million SEK | -8.09% |
| 2017 Q4 | 12.03 Million SEK | -27.37% |
| 2016 Q3 | 5.27 Million SEK | -3.9% |
| 2016 Q1 | 5.15 Million SEK | -12.62% |
| 2016 FY | 22.52 Million SEK | 13.24% |
| 2016 Q4 | 6.61 Million SEK | 25.3% |
| 2016 Q2 | 5.49 Million SEK | 6.6% |
| 2015 Q4 | 5.89 Million SEK | 64.73% |
| 2015 FY | 19.89 Million SEK | 22.36% |
| 2015 Q1 | 4.94 Million SEK | -3.08% |
| 2015 Q3 | 3.57 Million SEK | -34.73% |
| 2015 Q2 | 5.48 Million SEK | 10.97% |
| 2014 Q2 | 3.85 Million SEK | -9.35% |
| 2014 Q4 | 5.09 Million SEK | 67.11% |
| 2014 FY | 16.25 Million SEK | 39.12% |
| 2014 Q3 | 3.05 Million SEK | -20.92% |
| 2014 Q1 | 4.25 Million SEK | 32.72% |
| 2013 Q4 | 3.2 Million SEK | 13.69% |
| 2013 Q3 | 2.82 Million SEK | -15.82% |
| 2013 Q2 | 3.35 Million SEK | 44.96% |
| 2013 FY | 11.68 Million SEK | -65.89% |
| 2013 Q1 | 2.31 Million SEK | -78.68% |
| 2012 Q3 | 6.79 Million SEK | -21.19% |
| 2012 Q1 | 8.01 Million SEK | -36.21% |
| 2012 Q4 | 10.84 Million SEK | 59.61% |
| 2012 FY | 34.26 Million SEK | 27.8% |
| 2012 Q2 | 8.61 Million SEK | 7.59% |
| 2011 Q1 | -1.4 Million SEK | -124.89% |
| 2011 Q2 | 10.05 Million SEK | 817.49% |
| 2011 Q3 | 5.72 Million SEK | -43.08% |
| 2011 Q4 | 12.55 Million SEK | 119.49% |
| 2011 FY | 26.81 Million SEK | 274.05% |
| 2010 Q4 | 5.62 Million SEK | 578.89% |
| 2010 FY | 7.16 Million SEK | 0.0% |
| 2010 Q3 | 829 Thousand SEK | 16.6% |
| 2010 Q2 | 711 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Active Biotech AB (publ) | 44.8 Million SEK | -40.769% |
| Amniotics AB (publ) | 29.07 Million SEK | -116.968% |
| BioArctic AB (publ) | 89.62 Million SEK | 29.623% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 95.834% |
| Camurus AB (publ) | 1.05 Billion SEK | 94.047% |
| Cantargia AB (publ) | 290.01 Million SEK | 78.251% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -188.089% |
| CombiGene AB (publ) | 44.14 Million SEK | -42.889% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 55.886% |
| Genovis AB (publ.) | 88.19 Million SEK | 28.482% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 45.185% |
| Mendus AB (publ) | 129.13 Million SEK | 51.155% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -767.873% |
| Intervacc AB (publ) | 79.78 Million SEK | 20.941% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1042.906% |
| LIDDS AB (publ) | 27.75 Million SEK | -127.288% |
| Lipum AB (publ) | 37.3 Million SEK | -69.076% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -769.548% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 53.59% |
| NextCell Pharma AB | -576.01 Thousand SEK | 11050.507% |
| OncoZenge AB (publ) | 15.9 Million SEK | -296.586% |
| Saniona AB (publ) | 1.07 Million SEK | -5756.732% |
| Simris Alg AB (publ) | 38.64 Million SEK | -63.234% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 80.381% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 82.362% |
| Xintela AB (publ) | 57.31 Million SEK | -10.051% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 65.292% |
| Ziccum AB (publ) | 27.87 Million SEK | -126.261% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -330.472% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -122.68% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -284.592% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 79.46% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -47.957% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -256.71% |
| Corline Biomedical AB | 30.16 Million SEK | -109.086% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -8.695% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 24.158% |
| Aptahem AB (publ) | 10.01 Million SEK | -529.955% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 53.17% |
| Fluicell AB (publ) | 28.61 Million SEK | -120.418% |
| Biovica International AB (publ) | 133.72 Million SEK | 52.83% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -218.732% |
| AcouSort AB (publ) | 25.87 Million SEK | -143.766% |
| Abliva AB (publ) | 27.86 Million SEK | -126.358% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 67.402% |
| 2cureX AB (publ) | 36.51 Million SEK | -72.729% |
| I-Tech AB | 40.14 Million SEK | -57.111% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 92.661% |
| Cyxone AB (publ) | 28.21 Million SEK | -123.566% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 42.326% |
| Biosergen AB | 26.8 Million SEK | -135.283% |
| Nanologica AB (publ) | 69.88 Million SEK | 9.744% |
| SynAct Pharma AB | 224.49 Million SEK | 71.903% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -42.786% |
| BioInvent International AB (publ) | 441.4 Million SEK | 85.71% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -163.323% |
| Alzinova AB (publ) | 36.39 Million SEK | -73.308% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 78.23% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -702.887% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 43.13% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -329.095% |